Graves' Disease
Recent clinical, regulatory, research and industry developments relating to this disease.
The genetics of Graves' disease.
Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function?
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026Randomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDisease
- Q1 2027Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility Trial
- Q1 2028A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease
- Q2 2028A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
- Q3 2028A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
Clinical MilestonesViewHide
- 2026-08-21A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid DrugsResults expected Q2 2028
- 2026-08-05Randomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDiseaseResults expected Q4 2026
- 2026-08-03A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' DiseaseResults expected Q3 2028
- 2026-07-30A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' DiseaseResults expected Q1 2028
- 2026-01-27Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility TrialResults expected Q1 2027
- 2026-08-21ClinicalA Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid DrugsResults expected Q2 2028
- 2026-08-05ClinicalRandomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDiseaseResults expected Q4 2026
- 2026-08-03ClinicalA Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' DiseaseResults expected Q3 2028
- 2026-07-30ClinicalA Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' DiseaseResults expected Q1 2028
- 2026-01-27ClinicalImpact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility TrialResults expected Q1 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes3
- Gastrointestinal Microbiome1
- Graves Disease1
- Graves Ophthalmopathy1
Leading journals2
- Nutrients1
- Reviews in endocrine & metabolic disorders1
Leading researchers7
- Amrein K1
- Grixti L1
- Knezevic J1
- Lane LC1
- Pearce SH1
- Starchl C1
- Tmava Berisha A1
Affiliations (unnormalised)4
- Medical University of Graz1
- Royal Victoria Infirmary1
- The Great North Children's Hospital1
- Translational and Clinical Research Institute1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.